Aman Kumar, Oaktree's managing director, discusses direct lending in the life science sector, public-to-private transaction opportunities, and Oaktree's private credit strategy. He explores various sub-sectors within life sciences, attractive investment areas like immuno-oncology, and key markets. Kumar explains deal structuring, equity upside participation, leverage complexities, and pricing structure in life sciences lending. He also discusses conservative spending, non-dilutive financing in biotech and bio pharma markets, and the increase in public to private deals in the sector.